National Cancer Institute (NCI)s

National Cancer Institute (NCI)

444 Protocols (228 Active Accrual of new subjects, 216 Follow-up of previously enrolled subjects)

 12-C-0197:

A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD

 12-C-0118:

A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy

 12-C-0107:

Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study

 12-C-0081:

Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer

 12-C-0079:

A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer

 12-C-0068:

A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral rinse for Oral Chronic Graft-Versus-Host Disease

 12-C-0066:

Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors

 11-C-0247:

A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer Patients

 11-C-0200:

A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression

 11-C-0161:

A Phase I/II Study of the Mitogen Activated Protein Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

 11-C-0140:

A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors

 11-C-0136:

Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation

 11-C-0132:

Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer

 11-C-0123:

A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with

 11-C-0096:

Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

 11-C-0061:

Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors

 10-C-0174:

Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency

 10-C-0114:

A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

 10-C-0054:

Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation

 10-C-0025:

Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

 09-C-0024:

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults

 09-C-0019:

A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors

 09-C-0005:

Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease

 08-C-0214:

A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases

 08-C-0130:

A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas

 08-C-0079:

Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1

 08-C-0020:

A Phase II Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal Tumors

 07-C-0195:

Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Trea

 07-C-0121:

Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)

 06-C-0219:

An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors

 06-C-0134:

Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1

 05-C-0252:

Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas

 05-C-0152:

Variation in Gene Expression in Neurofibromatosis Type 1

 04-C-0275:

Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity

 04-C-0238:

A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors

 04-C-0232:

A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse

 02-C-0268:

Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer

 02-C-0212:

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

 02-C-0210:

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy

 02-C-0178:

Multidisciplinary Etiologic Study of Familial Testicular Cancer

 01-C-0030:

Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas

 01-C-0009:

Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study

 99-C-0099:

Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy

 78-C-0039:

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer

Previous 100 Protocols